GEN-MKT-18-7897-A
Jul 14, 2017 | Blogs, Food / Beverage | 0 comments
Don’t judge a nutritional supplement by its label, as often, government monitoring of ingredients begins after the product enters the consumer market1. Meanwhile, there may be additional additives not mentioned on the label as they are used to address supplement side effects. Such is the case in the United States where even though federal law requires supplements to carry a dietary supplement label or a substitutional term, monitoring begins once a supplement is on the market. In China meanwhile, the China Food and Drug Administration’s (CFDA) health product potential illegal additives list, clearly stipulates monitoring processes for additives in six different types of nutritional supplements including weight loss, blood sugar reduction, blood pressure reduction, anti-fatigue, sleep improvement and immune strengthening functions.Read Tech Note >
Keeping up with additives is no small job for the labs tasked with analysis. A research report by Grand View Research notes that “The rising sales of sports nutrition products in the U.S. and China along with new product launches are likely to have a significant impact on the industry. The market is expected to generate revenues worth USD 37.16 billion by 2024.2
Since drug interactions can be unclear, however, they continue to merit clarity. In the following application note, Use of X500R QTOF for Monitoring Unexpected Additives in Nutritional Supplements, researchers used the X500R QTOF high-resolution mass spectrometry and SCIEX OS software for quick and qualitative confirmation of 50 additives. Want to see how your lab can keep up with supplemental screening? Download the tech note to discover how you can overcome matrix interference in complex matrices for the accurate testing of additives such as atenolol, nitrendipine, nifedipine, glibenclamide, glipizide, rosiglitazone, and gliclazide.
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Posted by
You must be logged in to post a comment.
Share this post with your network